An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy

Kidney International

Volumn 88, Issue 6, 2015, Pages 1314-1322

  Nichols, Eva Maria ^a   Barbour, Thomas D ^b   Pappworth, Isabel Y ^a   Wong, Edwin K S ^a   Palmer, Jeremy M ^a   Sheerin, Neil S ^a   Pickering, Matthew C ^b   Marchbank, Kevin J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C3 glomerulopathy; Factor H; Mini FH; Therapeutic

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; RECOMBINANT COMPLEMENT FACTOR H; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C3 GLOMERULOPATHY; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPOSITION; CONTROLLED STUDY; GLOMERULOPATHY; HALF LIFE TIME; HEMOLYTIC UREMIC SYNDROME; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT OUTCOME;

EID: 84951570509     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.233     Document Type: Article

References (45)

1. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 1976; 144: 1147-1163
2. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry 2013; 52: 3949-3962
3. Weiler JM, Daha MR, Austen KF et al. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 1976; 73: 3268-3272
4. Langford-Smith A, Keenan TD, Clark SJ et al. The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J Innate Immun 2014; 6: 407-416
5. Clark SJ, Ridge LA, Herbert AP et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol 2013; 190: 2049-2057
6. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E et al. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-367
7. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089
8. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464
9. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756
10. Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant 2014
11. Le Quintrec M, Lionet A, Kandel C et al. Eculizumab for treatment of rapidly progressive c3 glomerulopathy. Am J Kidney Dis 2015; 65: 484-489
12. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424-428
13. Paixao-Cavalcante D, Hanson S, Botto M et al. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol 2009; 46: 1942-1950
14. Fakhouri F, de Jorge EG, Brune F et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78: 279-286
15. Sharma AK, Pangburn MK. Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system. Gene 1994; 143: 301-302
16. Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71: 1285-1295
17. Buttner-Mainik A, Parsons J, Jerome H et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J 2011; 9: 373-383
18. Huang Y, Qiao F, Atkinson C et al. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008; 181: 8068-8076
19. Cheng ZZ, Hellwage J, Seeberger H et al. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol 2006; 43: 972-979
20. Gordon DL, Kaufman RM, Blackmore TK et al. Identification of complement regulatory domains in human factor H. J Immunol 1995; 155: 348-356
21. Jokiranta TS, Zipfel PF, Hakulinen J et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett 1996; 393: 297-302
22. Goicoechea de Jorge E, Caesar JJ, Malik TH et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA 2013; 110: 4685-4690
23. Pechtl IC, Kavanagh D, McIntosh N et al. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011; 286: 11082-11090
24. Tortajada A, Montes T, Martinez-Barricarte R et al. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009; 18: 3452-3461
25. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S et al. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41: 81-84
26. Francis NJ, McNicholas B, Awan A et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012; 119: 591-601
27. Sim E, Palmer MS, Puklavec M et al. Monoclonal antibodies against the complement control protein factor H (beta 1 H). Biosci Rep 1983; 3: 1119-1131
28. Fenaille F, Le Mignon M, Groseil C et al. Site-specific N-glycan characterization of human complement factor H. Glycobiology 2007; 17: 932-944
29. Schmidt CQ, Slingsby FC, Richards A et al. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011; 76: 254-263
30. Li H, d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol 2009; 20: 678-684
31. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 2009; 46: 2808-2817
32. Schneider MC, Prosser BE, Caesar JJ et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009; 458: 890-893
33. Shaughnessy J, Lewis LA, Jarva H et al. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun 2009; 77: 2094-2103
34. Blanc C, Togarsimalemath SK, Chauvet S et al. Anti-Factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015; 194: 5129-5138
35. Hebecker M, Alba-Dominguez M, Roumenina LT et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013; 191: 912-921
36. Schmidt CQ, Bai H, Lin Z et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 2013; 190: 5712-5721
37. Ruseva MM, Peng T, Wang Y et al. Efficacy of targeted complement inhibition in experimental C3 glomerulopathy. In: Tambourgi DV, Fishelson Z (eds). XXV International Complement Workshop, Vol. 61. Elsevier: Rio de Janeiro, Brazil, 2014, p 256
38. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008; 88: 451-487
39. Jacobson AC, Weis JJ, Weis JH. Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner. J Immunol 2008; 180: 5057-5066
40. Harris CL. Functional assays for complement regulators. Methods Mol Biol 2000; 150: 83-101
41. Charreau B, Cassard A, Tesson L et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994; 58: 1222-1229
42. Yanagawa B, Spiller OB, Choy J et al. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 2003; 83: 75-85
43. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006; 3: e431
44. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990; 132: 191-195
45. Moesby L, Jensen S, Hansen EW et al. A comparative study of mono Mac 6 cells, isolated mononuclear cells and Limulus amoebocyte lysate assay in pyrogen testing. Int J Pharm 1999; 191: 141-149.